Compare ServiceNow Inc (NOW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs State Street SPDR S&P Biotech ETF — how do they compare? ServiceNow Inc trades at $139.71 (market cap $144.48B), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: ServiceNow Inc is far larger — about 14.3× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| NOW | XBI | |
|---|---|---|
Market Cap | $144.48B | $10.11B |
Volume | 11,801,699 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $189.26 | $169.55 |
52-Week Low | $83.00 | $104.99 |
Typical Hold Time | 54 Days | 37 Days |
Enterprise Value | $148.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.
ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
